Blood-brain barrier imaging as a potential biomarker for bipolar disorder progression

Lyna Kaminetsky\textsuperscript{a}, Kathleen A. Cairns\textsuperscript{b}, Ronel Veksler\textsuperscript{c}, Chris Bowen\textsuperscript{d}, Steven D. Beyea\textsuperscript{d}, Alon Friedmana\textsuperscript{a,\textsuperscript{c}}, Cynthia Calkine\textsuperscript{e}

\textsuperscript{a} Department of Medical Neuroscience, Dalhousie University, Sir Charles Tupper Building, 5850 College Street, Halifax, NS, B3H 4R2, Canada
\textsuperscript{b} Nova Scotia Health Authority, Mood Disorders Clinic, 5909 Veterans Memorial Lane, Halifax, NS, B3H 4R2, Canada
\textsuperscript{c} Department of Physiology and Cell Biology, Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel
\textsuperscript{d} Biomedical Translational Imaging Centre (BIOTIC), QEII Health Sciences Centre, and Department of Diagnostic Radiology, Dalhousie University, 1796 Summer Street, Halifax, NS, B3H 3A7, Canada
\textsuperscript{e} Departments of Psychiatry and Medical Neuroscience, Dalhousie University, Mood Disorders Clinic, 5909 Veterans Memorial Lane, Halifax, NS, B3H 2E2, Canada

A R T I C L E   I N F O

Keywords:
Blood-brain barrier
Dynamic contrast-enhanced MRI
Bipolar disorder
Depression
Anxiety
Insulin resistance

A B S T R A C T

Bipolar disorder affects approximately 2% of the population and is typically characterized by recurrent episodes of mania and depression. While some patients achieve remission using mood-stabilizing treatments, a significant proportion of patients show progressive changes in symptomatology over time. Bipolar progression is diverse in nature and may include a treatment-resistant increase in the frequency and severity of episodes, worse psychiatric and functional outcomes, and a greater risk of suicide. The mechanisms underlying bipolar disorder progression remain poorly understood and there are currently no biomarkers for identifying patients at risk. The objective of this study was to explore the potential of blood-brain barrier (BBB) imaging as such a biomarker, by acquiring the first imaging data of BBB leakage in bipolar patients, and evaluating the potential association between BBB dysfunction and bipolar symptoms. To this end, a cohort of 36 bipolar patients was recruited through the Mood Disorders Clinic (Nova Scotia Health Authority, Canada). All patients, along with 14 control subjects (matched for sex, age and metabolic status), underwent contrast-enhanced dynamic MRI scanning for quantitative assessment of BBB leakage as well as clinical and psychiatric evaluations. Outlier analysis has identified a group of 10 subjects with significantly higher percentages of brain volume with BBB leakage (labeled the “extensive BBB leakage” group). This group consisted exclusively of bipolar patients, while the “normal BBB leakage” group included the entire control cohort and the remaining 26 bipolar subjects. Among the bipolar cohort, patients with extensive BBB leakage were found to have more severe depression and anxiety, and a more chronic course of illness. Furthermore, all bipolar patients within this group were also found to have co-morbid insulin resistance, suggesting that insulin resistance may increase the risk of BBB dysfunction in bipolar patients. Our findings demonstrate a clear link between BBB leakage and greater psychiatric morbidity in bipolar patients and highlight the potential of BBB imaging as a mechanism-based biomarker for bipolar disorder progression.

1. Introduction

Bipolar disorder affects approximately 2% of the population, and is characterized by episodes affecting mood, activity levels, and ability to carry out day-to-day tasks (Kessler et al., 2005). A growing body of evidence suggests that treatment-resistant disease progression is common in bipolar patients, and may include a shift towards more frequent and severe episodes, worse depression, anxiety, socio/occupational dysfunction and increased risk of suicide (Hui et al., 2015). While the pathophysiology of bipolar disorder remains poorly understood, converging evidence points to the presence of neuroinflammation in bipolar patients (Naaldijk et al., 2016; Patel and Frey, 2015). In light of the increasingly recognized role of the brain’s microvasculature in neuroinflammation, here we set out to examine the potential link between blood brain barrier (BBB) dysfunction and bipolar disorder progression.

Under normal conditions the BBB restricts the entry of most blood-derived factors into the brain. This tight regulation of the brain’s environment is necessary for proper neuronal activity and is performed by the tightly connected membrane of endothelial cells within brain...
microvessels, and the mural and astrocytic cells engulffing it (Abbott et al., 2010). Hence, disruption of this complex interface allows the extravasation of blood-derived factors into the brain, causing neuroinflammatory responses which can initiate various pathways of neural dysfunction and degeneration (Sweeney et al., 2018).

In the past two decades dynamic contrast-enhanced (DCE-) magnetic resonance imaging (MRI) has been gaining popularity as the method of choice for assessing BBB leakage in living subjects (Heye et al., 2014). In this method, repeated scans of the brain are acquired to capture signal changes due to cross-BBB extravasation of an intravenously injected contrast agent. As the current gold standard for BBB assessment still relies on post-mortem tissue analysis, cross-validation of the two methods in the same individuals is not a trivial task. However, DCE-MRI studies have been used to identify BBB dysfunction in disorders such as multiple sclerosis (Ingrisch et al., 2012; Cramer et al., 2014; Varatharaj, 2019; Haider et al., 2019), stroke (Merali et al., 2017; Kassner et al., 2009; Serlin et al., 2019), brain tumors (Bergamino et al., 2013), epilepsy (Bar-Klein et al., 2017), traumatic brain injury (Weissberg et al., 2014; Tomkins et al., 2008), and dementia (Sweeney et al., 2018; Nation et al., 2018) — all of which were previously linked to BBB impairment in post-mortem studies. Moreover, while a large-scale validation of this approach is yet to be performed, two recent studies have successfully demonstrated the method's reproducibility (Wong et al., 2017) and biological validity (Varatharaj, 2019).

To date DCE-MRI has not been applied to the study of psychiatric disorders and the clinical correlates of BBB dysfunction in these disorders remain unknown. Thus, the goal of the present study was to obtain the first imaging evidence of BBB dysfunction in bipolar patients, and to test the association between BBB pathology and disease severity.

2. Results

2.1. Participants

A cohort of 36 bipolar patients was recruited for the study (23 bipolar type I and 13 bipolar type II). The average duration of illness among the patients was 28 ± 13 years, with an average onset at 22 ± 10 years of age. Bipolar disorder started with a depressive episode in 76% of patients, and about half (55%) have progressed to a chronic course of illness. The average age of the group was 49.1 ± 11.3 years and 70.6% were females. Control subjects were matched for sex, age and metabolic syndrome (Table 1). Compared to controls, bipolar patients scored significantly worse on scales of depression (Montgomery-Åsberg Depression Rating Scale), anxiety (Hamilton Anxiety Rating Scale), and capacity of carrying out day-to-day functions (Global Assessment of Functioning, Table 1). No differences in anthropometric or metabolic measures were identified between the groups (Table 1).

2.2. A sub-group of bipolar patients have a significantly higher level of BBB dysfunction

All participants underwent DCE-MRI scanning and quantitative maps of leakage rates were calculated for each brain voxel (Veksler et al., 2014; Chassidim et al., 2013) (Fig. 1A). The percent of brain tissue with pathological leakage rates was used as an overall measure of BBB dysfunction, revealing a high variability of values among the bipolar cohort (Fig. 1B). In order to identify subjects with significantly higher levels of BBB dysfunction, an outlier analysis was performed (based on the median + two standard deviations of all 50 subjects). Ten of the 50 subjects were identified as outliers (subjects with over 12.2% of the brain affected by leakage). The outlier group consisted exclusively of bipolar patients, and was labeled the “extensive BBB leakage” group. The group with the lower level of BBB dysfunction included the entire control cohort as well as the remaining 26 bipolar patients. Since there were no differences between the controls and patients within this group (Fig. 1C), it was collectively referred to as the “normal BBB leakage” group. To examine whether the differences between bipolar patients with extensive vs normal leakage were widespread (diffuse) or restricted to specific brain regions (focal), region-specific leakage was quantified in 126 anatomically/functionally significant brain regions and compared between the two groups. The comparison revealed a diffuse rather than focal difference, with 112 of the 126 regions showing significantly higher leakage in the “extensive BBB leakage” group (Fig. 1D, p < 0.05, corrected for multiple comparisons).

2.3. Extensive BBB leakage in bipolar patients is associated with greater psychiatric morbidity

To examine whether a higher level of BBB dysfunction corresponds to a worse bipolar outcome, we next compared the course of illness among the groups (episodic versus chronic), as well as levels of depression, anxiety, and socio/occupational functioning. Bipolar patients with extensive BBB leakage were found to have higher rates of chronic illness with more frequent and/or severe manic/depressive episodes (as exemplified in Fig. 2A and quantified in Fig. 2B). Moreover, extensive BBB leakage was found to be associated with greater severity of depression, anxiety, and socio/occupational dysfunction (Fig. 2B). No associations between BBB pathology and age or disease duration were found in our cohort.

| Table 1: Participant characteristics. |
|--------------------------------------|
| **Demographics**                     | **Bipolar Patients** | **Controls** | **p value** |
| Age                                  | 49.1 (1.9)           | 47.6 (2.9)   | 0.666       |
| Sex (% female)                       | 70.6                 | 71.4         | 1.000       |
| **Anthropometric and metabolic measures** |
| Body mass index (BMI)                | 30.1 (1.1)           | 28.2 (1.5)   | 0.358       |
| Waist-to-hip ratio                   | 0.9 (0.02)           | 0.9 (0.03)   | 0.230       |
| Risk of cardiovascular disease       | 8.6 (1.5)            | 4.9 (0.8)    | 0.469       |
| Framingham heart age (Wilson et al., 1998) | 53.0 (5.3)        | 47.7 (2)     | 0.602       |
| Metabolic syndrome (Alberti et al., 2009) | 27.8                 | 15.4         | 0.474       |
| Insulin resistance (HOMA-IR score, Esteghamati et al., 2010) | 2.7 (0.3)     | 1.7 (0.2)    | 0.056       |
| **Psychiatric characteristics**      |                      |              |             |
| Depression severity (MADRS score, Hawley et al., 2002) | 18.1 (2.4)     | 19.0 (4.9)   | <0.001      |
| Anxiety severity (HAM-A score, Leentjens et al., 2011) | 11.8 (1.5)      | 2.0 (0.4)    | <0.001      |
| Global Assessment of Functioning (GAF score, Hall, 1995) | 66.8 (0.5)     | 92.1 (0.7)   | <0.001      |
| **Medication use (% patients)**      |                      |              |             |
| Lithium                              | 72%                  | ...          | ...         |
| Antiepileptics                       | 67%                  | ...          | ...         |
| Atypical antipsychotics              | 56%                  | ...          | ...         |
| Antidepressants                      | 44%                  | ...          | ...         |
| Benzodiazepines                      | 56%                  | ...          | ...         |
| Melatonin                            | 19%                  | 0            | 0.169       |
| Blood pressure medication            | 14%                  | 14           | 1.000       |
| Cholesterol medication               | 14%                  | 0            | 0.304       |

Mean (standard error), unless otherwise indicated. Continuous variables were compared using the Wilcoxon rank sum test, and categorical variables were compared using Fisher's Exact Test. MADRS, Montgomery-Åsberg Depression Rating Scale; HAM-A, Hamilton Anxiety Rating Scale; HOMA-IR, homeostatic model assessment of insulin resistance.
2.4. Extensive BBB leakage is associated with metabolic dysregulation, yet not with class of mood-stabilizing drugs

Bipolar patients with extensive BBB leakage were found to have higher body-mass indices, elevated risk of cardiovascular disease, and advanced heart age (Fig. 3). Furthermore, all patients within the “extensive BBB leakage” group were also found to have comorbid insulin resistance (homeostatic model assessment of insulin resistance >1.8, Esteghamati et al., 2010). Notably, while all subjects with extensive BBB leakage had insulin resistance, not all subjects with insulin resistance had extensive BBB leakage (with four insulin resistant controls and 12 insulin resistant bipolar patients having BBB leakage within the normal range). No patients were receiving anti-diabetic or insulin sensitizing drugs. No differences in the class of mood stabilizing treatments were found between the normal and extensive BBB leakage groups.

3. Discussion

This study presents the first imaging of BBB leakage in bipolar patients. Using dynamic contrast-enhanced MRI, we show that a higher level of dysfunction (i.e. extensive BBB leakage), affects 28% of the bipolar cohort and none of the controls. The study further shows that patients with extensive BBB leakage experience a more chronic form of illness with greater severity of depression, anxiety and socio/occupational dysfunction. Our findings suggest that BBB imaging holds potential as a mechanism-based biomarker for the psychiatric deterioration experienced by a sub-group of bipolar patients.

We propose that BBB leakage may impact the functionality of the affected brain regions, leading to region-associated symptomatology. This hypothesis is supported by a recent imaging study in subjects with cognitive decline, linking cognitive impairment to BBB dysfunction in the hippocampus (Nation et al., 2018). Larger cohort studies are needed to determine the association between region-specific BBB dysfunction and the diverse symptoms of bipolar progression. Moreover, future large-scale prospective studies are needed for assessing the sensitivity and specificity of DCE-MRI based BBB assessment, before it can become part of routine medical practice.

Our study also links BBB damage in bipolar patients to insulin resistance, in line with recent evidence associating insulin resistance with vascular dysfunction in the brain and increased risk of dementia (Hughes and Craft, 2016). Insulin resistance is known to be more common in bipolar patients compared to the general population (Brietzke et al., 2011; Calkin et al., 2015), yet the mechanisms underlying this phenomenon remain poorly understood (Calkin, 2019). While atypical antipsychotics were suggested to cause insulin resistance in patients with bipolar disorder and schizophrenia (Vancampfort et al., 2016; Burghardt et al., 2018; Correll et al., 2008), we found no association between the use of atypical antipsychotics and insulin resistance or BBB leakage. Future studies are warranted to better understand the
high rates of insulin resistance observed in bipolar patients.

While our study is the first to show direct imaging evidence of BBB dysfunction in psychiatric patients, future studies are needed to fully elucidate the mechanisms mediating the psychiatric decline associated with BBB dysfunction and to determine whether vascular-protecting therapies may prove beneficial for bipolar disorder treatment.

4. Conclusions

Our study reveals an association between BBB pathology and worse psychiatric morbidity in bipolar patients. Our findings further suggest that BBB imaging offers promise as a new biomarker for bipolar disorder progression.

5. Methods

5.1. Participants

The study was approved by the Nova Scotia Health Authority Research Ethics Board (1021507). A total of 36 adult patients (over 18 years of age) were recruited to the study through the Mood Disorders Clinic (Nova Scotia Health Authority, Canada). Subjects underwent a detailed psychiatric interview using the schedule for affective disorders and schizophrenia (SADS-L, Endicott and Spitzer, 1978) to diagnose...
bipolar disorder. Diagnoses required a consensus of at least 3 psychiatrists and were based on the DSM-5 criteria (American Psychiatric Association 2013). As patients with type I versus II bipolar disorder differ primarily in severity of manic episodes, we did not exclude patients based on this criterion. Mood symptoms were rated using the Montgomery-Åsberg Depression Rating Scale (MADRS, Hawley et al., 2002), Hamilton Anxiety Rating Scale (HAM-A, Leentjens et al., 2011), and the Global Assessment of Functioning Scale (GAF, reflecting illness effects on social, occupational, and psychological functioning, Hall, 1995). Course of illness was determined using the affective morbidity index (AMI, rating the severity and length of manic/depressive episodes, Berghofer et al., 2008), patient interviews, detailed review of medical records, and analysis of daily mood ratings. Additional data collection included: blood pressure, body mass index (BMI), the homeostatic model assessment of insulin resistance (HOMA-IR, calculated based on fasting levels of blood glucose and insulin, Esteghamati et al., 2010), and Framingham risk scores (heart age and risk of cardiovascular disease, Wilson et al., 1998).

A group of 14 control subjects was also recruited and was matched for sex, age and metabolic status to the bipolar cohort. The same schedule used for diagnosing bipolar disorder (SADS-L), was used to confirm a lack of psychiatric history in this group. The control group also underwent the above-mentioned protocol of interviews and assessments.

Participants with diabetes, pregnancy, or contradiction to MRI or contrast-enhancement (estimated glomerular filtration rate < 60) were excluded from the study. All participants provided informed consent prior to enrollment.

5.2. BBB imaging

5.2.1. DCE-MRI acquisition and preprocessing

Images were acquired using a 3T MRI scanner (Discovery MR750, GE Healthcare, Waukesha, WI), with a 32-channel MR Instruments head coil. The sequences acquired for BBB assessment included: (1) a T1-weighted 3D sagittal anatomical scan (BRAVO, TE/TR = 2/6 ms, TI = 450 ms, FOV 22.4 cm, acquisition matrix 224 × 224 × 168, voxel size 1 × 1 × 1 mm, acceleration 2, averages 2, scan time 5 min 42 s); (2) a T1-weighted 3D axial slice sequence with variable flip angles (2-10-30°,DESPOT1, TE/TR = 2/4 ms, FOV 24 cm, acquisition matrix: 192 × 192 × 34, voxel size 1.25 × 1.25 × 6 mm, scan time 6 min 39 s) for the calculation of pre-contrast T1 map (Deoni et al., 2005); and (3) a T1-weighted 3D axial dynamic scan (LAVA, TE/TR = 2/4 ms, FOV 24 cm, acquisition matrix: 192 × 192 × 34, voxel size 1.25 × 1.25 × 6 mm, flip angle 15°, averages 1, Δt = 20 Sec) acquired between minutes 6 and 20 after intravenous injection enhanced of the magnetic contrast Gadobenate Dimeglumine (0.1 mmol/kg, MultiHance, Bracco Imaging Canada, travenous injection enhanced of the magnetic contrast Gadobenate平均s 1 , Weissberg et al., 2014; Chassidim et al., 2013), which estimates the percent of suprathreshold voxels was used for sex, age and metabolic status to the bipolar cohort. The same schedule used for diagnosing bipolar disorder (SADS-L), was used to confirm a lack of psychiatric history in this group. The control group also underwent the above-mentioned protocol of interviews and assessments.

Participants with diabetes, pregnancy, or contradiction to MRI or contrast-enhancement (estimated glomerular filtration rate < 60) were excluded from the study. All participants provided informed consent prior to enrollment.

5.2. BBB imaging

5.2.1. DCE-MRI acquisition and preprocessing

Images were acquired using a 3T MRI scanner (Discovery MR750, GE Healthcare, Waukesha, WI), with a 32-channel MR Instruments head coil. The sequences acquired for BBB assessment included: (1) a T1-weighted 3D sagittal anatomical scan (BRAVO, TE/TR = 2/6 ms, TI = 450 ms, FOV 22.4 cm, acquisition matrix 224 × 224 × 168, voxel size 1 × 1 × 1 mm, acceleration 2, averages 2, scan time 5 min 42 s); (2) a T1-weighted 3D axial slice sequence with variable flip angles (2-10-30°,DESPOT1, TE/TR = 2/4 ms, flip angle 15°, averages 2, FOV 24 cm, acquisition matrix 192 × 192 × 34, voxel size 1.25 × 1.25 × 6 mm, scan time 6 min 39 s) for the calculation of pre-contrast T1 map (Deoni et al., 2005); and (3) a T1-weighted 3D axial dynamic scan (LAVA, TE/TR = 2/4 ms, FOV 24 cm, acquisition matrix: 192 × 192 × 34, voxel size 1.25 × 1.25 × 6 mm, flip angle 15°, averages 1, Δt = 20 Sec) acquired between minutes 6 and 20 after intravenous injection enhanced of the magnetic contrast Gadobenate Dimeglumine (0.1 mmol/kg, MultiHance, Bracco Imaging Canada, Montreal, QC). All sequences were registered and normalized to MNI coordinates using SPM12 (University College London, www.fil.ion.ucl.ac.uk/spm).

5.2.2. Image analysis

As extravasation of contrast agent due to cross-BBB leakage leads to increased T1 signaling in the affected tissue, it allows quantitative assessment of contrast accumulation in the tissue and hence the contrast leakage rate. To achieve this, T1 intensities are first converted to contrast concentration values (Deoni et al., 2005), and concentration-time curves are constructed for every brain voxel. The concentration-time curves can next be fitted to one of several pharmacokinetic models, allowing the calculation of parameters corresponding to leakage rates. Here we used the linear model (Serlin et al., 2019; Wong et al., 2017; Veksler et al., 2014; Chassidim et al., 2013), which estimates the leakage rate Ki (mMol/min) by calculating the slope of each concentration-time curve between 6-20 min. To compensate for inter-
Serlin, Y. et al. Blood-brain barrier leakage in TIA. 1266–1269 (2019). 10.1161/STROKEAHA.119.025247.

Bergamino, M, et al., 2013. Measurement of blood-brain barrier permeability with T1-weighted dynamic contrast-enhanced MRI in brain tumors: a comparative study with two different algorithms. ISBN Neurosci., 905279 2013.

Bar-Klein, G, et al., 2017. Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis. Brain 140, 1692–1705.

Weissberg, I, et al., 2014. Imaging blood-brain barrier dysfunction in football players. JAMA Neurol. 71.

Tomkins, O, et al., 2008. Blood-brain barrier disruption in post-traumatic epilepsy. J. Neurol. Neurosurg. Psychiatry 79, 774–777.

Nation, D, et al., 2018. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med in press.

Wong, S.M, 2017. Measuring subtle leakage of the blood–brain barrier in cerebrovascular disease with DCE-MRI: test–retest reproducibility and its influencing factors. et al 159–166. https://doi.org/10.1002/jmri.25540.

Wilson, P. W. F. et al. Prediction of coronary heart disease using risk factor categories. (1998).

Alberti, K.G.M.M, et al., 2009. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; World Heart Federation; International. Circulation 120, 1640–1645.

Esteghamati, A, et al., 2010. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr. Metab. (Lond). 7, 26.

Hawley, C.J., Gale, T.M., Sivakumaran, T., 2002. Defining remission by cut off score on the MADRS: selecting the optimal value. J. Affect. Disord. 72, 177–184.

Holl, R.C., 1995. Global assessment of functioning. Psychosomatics 36, 267–275.

Varatharaj, A., et al., 2019. Blood–brain barrier permeability measured using dynamic contrast-enhanced magnetic resonance imaging: a validation study. J. Physiol. 597, 699–709.

Vekler, R., Shelef, L, Friedman, A., 2014. Blood-brain barrier imaging in human neuropathologies. Arch. Med. Res. 45, 646–652.

Chassidim, Y, et al., 2013. Quantitative imaging assessment of blood-brain barrier permeability in humans. Fluids Barriers CNS 10, 9.

Hughes, T.M., Craft, S., 2016. The role of insulin in the vascular contributions to age-related dementia. Biochim. Biophys. Acta - Mol. Basis Dis. 1862, 983–991.

Brietzke, E, et al., 2011. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev. Neurother. 11, 1017–1028.

Calkin, C.V, et al., 2015. Insulin resistance and outcome in bipolar disorder. Br. J. Psychiatry 206, 52–57.

Calkin, C.V., 2019. Annals of Medicine Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann. Med. 0, 1–13.

Vancampfort, D, et al., 2016. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 15, 166–174.

Burghardt, K.J, et al., 2018. Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 83, 55–63.

Correll, C.U., Frederickson, A.M., Kane, J.M., Manu, P., 2008. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 10, 798–797.

Endicott, J., Spitzer, R.J., 1978. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry 35, 837–844.

American Psychiatric Association, 2013. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association.

Deoni, S. C. L., Peters, T. M. & Rutt, B. K. High-resolution T1 and T2 mapping of the brain in a clinically acceptable time with DESPOT1 and DESPOT2. 241, 237–241 (2005).